Clinical trial · Observational
Circulating Tumour Cells in Patients With Peritoneal Metastases
Cirkulerande Tumörceller Hos Patienter Med Bukhinnespridda tumörer
NCT04083547CI-TRIAL-00048099completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study aims to evaluate the prognostic value of circulating tumour cells (CTC) in patients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy due to gastrointestinal cancers that have spread to the peritoneum.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Circulating Tumor Cell | — | UNRESOLVED | — |
| Hyperthermic Intraperitoneal Chemotherapy | — | UNRESOLVED | — |
| Peritoneal Metastases | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| iCellate | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- HIPEC group
- description
- All patients undergoing HIPEC will asked to join this prospective study.
- interventionNames
- Diagnostic Test: iCellate
Primary outcomes (1)
- measure
- Prognostic value
- timeFrame
- 2 year.
- description
- Prediction of survival and recurrence according to the occurrence of CTCs.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: * Peritoneal metastases being treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy Exclusion Criteria: * None
References
Publications (0)
Data not yet available
No reference posted for this study.